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Objective: To investigate whether parity, age at menarche, menopausal status, age at menopause, use of
oral contraceptives (OC) or use of hormone replacement therapy (HRT) were associated with total knee
replacement (TKR) or total hip replacement (THR) due to primary osteoarthritis.
Method: In a prospective cohort study of 30,289 women from the second and third surveys of the Nord-
Trøndelag Health Study, data were linked to the Norwegian Arthroplasty Register (NAR) in order to
identify TKR or THR due to primary osteoarthritis. Cox proportional hazards models were used to esti-
mate the hazard ratios (HRs).
Results: We observed 430 TKRs and 675 THRs during a mean follow-up time of 8.3 years. Increasing age
at menarche was inversely associated with the risk of TKR (P-trend < 0.001). Past users and users of
systemic HRT were at higher risk of TKR compared to never users (HR 1.42 (95% confidence interval (CI)
1.06e1.90) and HR 1.40 (95% CI 1.03e1.90), respectively). No association was found between parity, age at
menarche, menopausal status, age at menopause, oral contraceptive use or HRT use and THR.
Conclusion: We found that increasing age at menarche reduced the risk of TKR. Past users and users of
systemic HRT were at higher risk of TKR compared to never users. Parity did not increase the risk of THR
or TKR.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis is probably the result of a complex interplay be-






er Ltd on behalf of Osteoarthritis R
d/4.0/).understanding of the risk factors and, thereby, groups at risk, would
make it possible to target effective public health preventions1.
There is a rise in osteoarthritis prevalence in women after
menopause2. The findings from epidemiologic studies on repro-
ductive history (parity, age at menarche, menopausal status and
age at menopause) and hormonal factors (oral contraceptives (OC)
and hormone replacement therapy (HRT)) in relation to osteoar-
thritis have been conflicting. Increasing parity has been reported as
a risk factor for radiographic osteoarthritis in the knee3 as well as
total knee replacement (TKR) and total hip replacement (THR)4.
However, some studies have not found any association between
parity and radiographic joint space narrowing, osteophytes or
changes in either cartilage volume or cartilage defects5. A large,esearch Society International. This is an open access article under the CC BY-NC-ND
A.I. Hellevik et al. / Osteoarthritis and Cartilage 25 (2017) 1654e1662 1655prospective cohort study reported that low age at menarche
increased the risk of TKR4, but this finding has not yet been
confirmed by other studies. The use of OC has not been associated
with osteoarthritis in most studies5e8, except one that reported a
possible increased risk of THR9. HRT has been shown to have a
protective effect on osteoarthritis in some studies7,10,11, while
others have found it to have no effect12e15 or even adverse effects4.
The aim of this study was to investigate the association between
reproductive history and use of hormonal therapies and the risk of
TKR or THR due to osteoarthritis in a prospective cohort study.
Methods
In the Nord-Trøndelag Health Study (HUNT)16 all inhabitants of
Nord-Trøndelag county  20 years of age were invited to partici-
pate in three surveys: HUNT1 (1984e1986), HUNT2 (1995e1997)
and HUNT3 (2006e2008)17. In total, 35,280 women participated in
HUNT2 (75.5% of those invited), and 27,758 in HUNT3 (58.7% of
those invited)17. Our study only included baseline data fromHUNT2
or HUNT3 as these surveys included questionnaire and interview
data on reproductive history and covariates. We included women
aged 30 years at baseline, and our study population consisted of
11,746 participants from HUNT2, 20,459 participants of both
HUNT2 and HUNT3 and 4652 participants from HUNT3 alone. For
those who participated in both HUNT2 and HUNT3, we used
baseline measurements from HUNT3 in order to include as much
information as possible on reproductive history and eventual use of
HRT. In this study we defined reproductive history as parity, age at
menarche, years of menstruation and age at menopause. HormonalFig. 1. Flowtherapies included use of OC and use of HRT. Height and weight
were measured by trained personnel. Body mass index (BMI) was
calculated as weight in kilograms divided by squared height in
metres. Bilateral oophorectomy in premenopausal women induces
premature menopause18, and womenwho undergo a hysterectomy
with ovarian preservation may almost double their risk of prema-
ture menopause compared to women with intact uteri19. We
therefore chose to exclude both of these groups at
baseline (n ¼ 3710). After also excluding 1183 participants with
joint replacement before recruitment, 91 with missing date of
operation, 436 with missing BMI and 1148 with missing informa-
tion on smoking, the analyses included 30,289 women (Fig. 1).
For follow-up, we identified cases with a TKR or THR due to
primary osteoarthritis, according to the operating surgeon, using
information from the Norwegian Arthroplasty Register (NAR). This
linkage was conducted using the 11-digit personal identification
number that is unique to each Norwegian citizen. NAR contains a
record of over 95% of all TKRs and THRs in Norway20. If a person had
more than one arthroplasty, only the first procedure was consid-
ered as the event.
Cox proportional hazards models were used to estimate the
hazard ratios (HRs) of TKR and THR according to parity (nullipa-
rous, 1, 2, 3, 4þ births), age at menarche (11,12,13,14, 15þ years),
menopausal status (pre/peri- and postmenopausal), age at
menopause (48, 49e51, 52þ years), years of menstruation (age
at menopause minus age at menarche), oral contraceptive use
(never or ever, and duration of use) and HRT use (never, past,
current; local or systemic and duration of use). Age was used as
the time scale in the analyses. Model 1 adjusted for BMIchart.
A.I. Hellevik et al. / Osteoarthritis and Cartilage 25 (2017) 1654e16621656(continuous) and smoking (never, former or current). The fully
adjusted model 2 also adjusted for physical activity (none, me-
dium, hard) and other reproductive variables as appropriate for
the individual exposures. Each exposure was analysed for its
interrelationship with other potential hormone-related con-
founders in a direct acyclic graph (DAG), resulting in a slightly
different set of confounders for each exposure (Table A,
Appendix). In these DAG analyses, diabetes was only found to be
a potential confounder to parity and age at menarche, and thus
only adjusted for in these two analyses.
Information on education level was only available for 8745
participants from HUNT2, and an additional sensitivity analysis
adjusting for education was performed on this group. Education
level was evaluated to be a confounder to parity, oral contraceptive
use and HRT (Tables B and C, Appendix), and was defined as the
highest level of completed education (primary/vocational, sec-
ondary or post-secondary).
The analyses examining age at menopause were limited to
postmenopausal women who had never used HRT. The tests for
linear trends were based on the categorical variables scored as the
mean of each category. All statistical analyses were two-sided with
a significance level of P < 0.05. The analyses were performed using
Stata 14.0/SE (StataCorp LP, College Station, TX, USA). Tests based on
Cox regression methods showed no evidence that proportional
hazard assumptions were violated.
Ethics
The participants signed written informed consent for participa-
tion in HUNT, NAR and linkage of data to national health registries.Table I
Study population characteristics at baseline (OC: Oral contraceptives; HRT: Hormone rep
n % Mean age SD BMI
All women
Parity
Nulliparous 1168 4.0 58.2 18.9 27.0
1 2966 10.3 53.6 16.2 26.9
2 10,649 36.8 52.7 14.2 26.6
3 8818 30.5 55.0 14.2 26.9
4 5322 18.4 63.6 14.1 27.9
Missing 1366 54.9 16.5 27.1
Age at menarche, years*
11 2683 9.2 50.7 12.9 28.5
12 5502 18.9 52.2 14.1 27.6
13 7554 26.0 53.2 14.5 27.0
14 7227 24.8 57.2 15.2 26.6
15 6129 21.1 60.5 15.4 26.2
Missing/unknown 1194 64.4 16.6 27.1
Menopausal statusy
Pre/peri 10,336 40.9 41.9 6.9 26.5
Post 14,922 59.1 65.8 10.2 27.4
Missing/unknown 2855 63.2 16.7 27.0
Age at menopause, yearsz
48 4815 32.3 64.7 11.2 27.3
49e51 5090 34.1 66.6 10.4 27.3
52 5017 33.6 65.9 9.0 27.6
OC usex
Never 6202 34.2 56.7 9.7 27.4
Ever 11,924 65.8 46.0 9.8 26.5
Missing 5733 50.1 11.1 26.9
HRT use
Never 22,203 83.0 52.3 14.5 26.9
Past 2536 9.5 64.4 9.5 27.1
Current 2003 7.5 64.4 10.2 27.1
Missing 3547 65.5 16.5 27.1
* Asked of women who were between 19 and 55 years old in HUNT3, but asked of all
y Excluded those with amenorrhoea after surgery or radiotherapy (n ¼ 2176).
z Only in postmenopausal women.
x Only information in women  70 years.This study was approved by the Norwegian Regional Committee for
Ethics in Medical Research (2013/151/REK Sør-Øst C).
Results
For the 30,289 women included in the study population, the
mean age at baseline was 55.7 and mean follow-up time was 8.3
years (SD 4.5). In total, 430 participants had a primary TKR, and 675
had a THR, due to primary osteoarthritis.
Women who reported age at menarche of 11 years were older
at baseline than those who reported menarche at 15 years
(Table I). Never users of OC were older than ever users, and past or
current users of HRT were older than never users. BMI slightly
decreased with increasing age at menarche. A lower portion of the
women with higher age at menarche smoked. There was a higher
prevalence of diabetes in women who were never oral contracep-
tive users. Hard physical activity was more prevalent in premeno-
pausal women and oral contraceptive users. Women that received a
TKR or THR during follow-up were older, and there were a higher
percentage of past or current HRT users than among those who did
not get a joint replacement (Table II).
Increasing ageatmenarchewas inverselyassociatedwith the risk
of TKR (P-trend < 0.001) (Table III). Compared to womenwith early
menarche, those with menarche at 14 years and 15 years had a
significantly lower risk of TKR (HR 0.64, 95% confidence interval (CI)
0.43e0.95; and HR 0.52, 95% CI 0.34e0.80; respectively). The
number of years of menstruation between menarche and meno-
pausewas not associatedwith TKR. Past users of HRTwere at higher
risk of TKR compared to never users (HR 1.42, 95% CI 1.06e1.90), but
only thosewho used systemic HRTcompared to local treatment (HRlacement therapy)
SD Current smokers (%) Diabetes (%) Hard physical activity (%)
missing ¼ 28 missing ¼ 6253
5.1 28.4 4.8 36.4
5.2 33.4 3.9 44.2
4.6 29.9 3.3 49.3
4.7 27.5 4.0 48.5
4.9 25.8 7.0 39.3
5.6 22.2 4.3 53.7
5.4 33.7 5.6 49.9
5.0 29.7 4.4 47.2
4.7 29.4 3.4 48.2
4.6 27.8 4.2 47.0
4.5 26.1 4.6 43.9
4.9 20.8 5.2 34.4
4.9 32.1 1.4 50.5
4.7 25.0 6.2 44.6
5.0 31.5 6.6 32.6
4.9 48.2 5.7 42.7
4.6 31.6 6.3 44.1
4.7 20.3 6.6 47.0
5.0 29.8 4.6 46.3
4.7 31.4 1.9 52.4
5.0 37.7 3.1 42.1
4.9 29.2 3.5 48.4
4.6 24.2 5.3 48.0
4.4 23.0 5.4 46.4
4.9 29.8 7.6 30.9
women in HUNT2.
Table II







Mean age, years (SD) 55.7 (15.2) 64.3 (10.6) 65.6 (10.5)
BMI, mean (SD) 27.0 (4.8) 30.8 (5.3) 28.7 (4.8)
Current smokers, n (%) 8613 (28.4) 83 (19.3) 159 (23.6)
Diabetes, n (%) 1293 (4.3) 23 (5.4) 33 (4.9)
Hard physical activity, n (%) 11,200 (37.0) 139 (39.8) 232 (42.3)
Parity, mean (SD) 2.6 (1.3) 2.9 (1.4) 2.9 (1.5)
Age at menarche, mean (SD)* 13.4 (1.5) 13.2 (1.5) 13.6 (2.0)
Years of menstruation, mean (SD) 36.0 (4.6) 36.6 (4.7) 36.2 (4.6)
Postmenopausal, n (%)y 14,922 (59.1) 341 (88.1) 515 (88.8)
Age at menopause, mean (SD)z 49.6 (4.4) 49.8 (4.4) 49.9 (4.0)
Ever users of oral contraceptives, n (%)x 11,924 (65.8) 103 (44.2) 133 (40.8)
Past users of HRT, n (%) 2536 (9.5) 69 (18.7) 88 (15.3)
Current users of HRT, n (%) 2003 (7.5) 57 (15.5) 95 (16.6)
* Asked of the women who were between 19 and 55 years old in HUNT3, but asked of all women in HUNT2.
y Excluded those with amenorrhoea after surgery or radiotherapy (n ¼ 2176).
z Only in postmenopausal women.
x Only information in women  70 years.
Table III
Reproductive history and use of hormonal medication, and risk of total knee replacement (TKR) (OC: Oral contraceptives; HRT: Hormone replacement therapy)
Population at risk Person years Cases Model 1* Model 2y
HR 95% CI HR 95% CI
Parity
Nulliparous 1168 12,610 17 1 Ref 1 Ref
1 2966 26,173 27 0.79 (0.43e1.45) 0.57 (0.28e1.19)
2 10,649 86,907 127 1.20 (0.72e2.00) 0.91 (0.50e1.67)
3 8818 71,050 134 1.28 (0.77e2.12) 0.88 (0.48e1.61)
4 5322 44,731 111 1.04 (0.62e1.73) 0.7 (0.38e1.30)
P linear trend 0.55 0.55
Age at menarche, years
11 2683 21,502 48 1 Ref 1 Ref
12 5502 45,203 83 0.81 (0.56e1.15) 0.83 (0.56e1.23)
13 7554 62,328 105 0.77 (0.55e1.09) 0.70 (0.48e1.03)
14 7227 59,988 104 0.68 (0.48e0.96) 0.64 (0.43e0.95)
15 6129 50,698 78 0.58 (0.40e0.84) 0.52 (0.34e0.80)
P linear trend 0.002 0.001
Menopausal status
Pre/peri 10,336 91,247 46 1 Ref 1 Ref
Post 14,922 112,668 341 0.95 (0.63e1.44) 1.16 (0.72e1.87)
Age at menopause, years
48 4815 37,504 111 1 Ref 1 Ref
49e51 5090 38,187 105 0.92 (0.70e1.20) 0.88 (0.64e1.21)
52 5017 36,976 125 0.99 (0.77e1.29) 0.98 (0.73e1.32)
Years of menstruation 14,386 250,254 430 1.01 (0.99e1.04) 1.02 (0.99e1.04)
OC use
Never 6202 56,109 130 1 Ref 1 Ref
Ever 11,924 96,117 103 1.37 (1.03e1.84) 1.36 (1.00e1.86)
Years of OC use 11,488 90,646 94 0.99 (0.93e1.06) 1.01 (0.95e1.09)
HRT use
Never 22,203 175,094 243 1 Ref 1 Ref
Past 2536 18,035 69 1.45 (1.10e1.90) 1.42 (1.06e1.90)
Current 2003 16,964 57 1.36 (1.02e1.82) 1.25 (0.90e1.73)
HRT use by site
Never 22,203 175,094 243 1 Ref 1 Ref
Local 2197 16,539 62 1.33 (1.00e1.76) 1.23 (0.90e1.68)
Systemic 2342 18,460 64 1.49 (1.13e1.98) 1.40 (1.03e1.90)
Years of HRT use 3370 22,306 99 1.02 (0.99e1.05) 1.03 (1.00e1.06)
* Adjusted for age, BMI and smoking.
y Adjusted for age, BMI, smoking and physical activity in all analyses. Additional adjustment for diabetes, parity, menarche, menopausal status, oral contraceptives and
hormone replacement therapy as appropriate in each DAG analysis.
A.I. Hellevik et al. / Osteoarthritis and Cartilage 25 (2017) 1654e1662 16571.40, 95% CI 1.03e1.90). Ever users of OC had a higher risk of TKR (HR
1.38, 95% CI 1.03e1.84), but this association was only borderline
significant in the fully adjusted model (HR 1.36, 95% CI 1.00e1.86).
No association was found between parity, age at menarche,
postmenopausal status or oral contraceptive use and THR (Table IV).
Current HRT users had increased risk of THR after adjustment forage, BMI and smoking, but this associationwas no longer significant
in the fully adjustedmodel. There was, however, an increased risk of
THR associated with years of HRT use (HR 1.04, 95% CI 1.01e1.07).
The vast majority of past/current HRT users were postmenopausal
women (n ¼ 4046), compared to pre/perimenopausal women
(n ¼ 329) (data not shown).
Table IV
Reproductive history and use of hormonal medication, and risk of total hip replacement (THR) (OC: Oral contraceptives; HRT: Hormone replacement therapy).
Population at risk Person years Cases Model 1* Model 2y
HR* 95% CI HRy 95% CI
Parity
Nulliparous 1168 12,610 25 1 Ref 1 Ref
1 2966 26,173 55 1.17 (0.73e1.88) 1.12 (0.58e2.18)
2 10,649 86,907 209 1.43 (0.94e2.17) 1.56 (0.86e2.81)
3 8818 71,050 186 1.30 (0.85e1.97) 1.42 (0.79e2.57)
4 5322 44,731 184 1.29 (0.85e1.97) 1.34 (0.74e2.44)
P linear trend 0.57 0.61
Age at menarche, years
11 2683 21,502 49 1 Ref 1 Ref
12 5502 45,203 118 1.04 (0.75e1.45) 1.15 (0.78e1.71)
13 7554 62,328 155 0.96 (0.70e1.33) 1.00 (0.68e1.47)
14 7227 59,988 177 0.93 (0.67e1.28) 1.04 (0.71e1.53)
15 6129 50,698 163 0.92 (0.67e1.28) 1.07 (0.73e1.58)
P linear trend 0.352 0.968
Menopausal status
Pre/peri 10,336 91,247 65 1 Ref 1 Ref
Post 14,922 112,668 515 0.99 (0.70e1.41) 0.97 (0.67e1.40)
Age at menopause, years
48 4815 37,504 156 1 Ref 1 Ref
49e51 5090 38,187 185 1.13 (0.92e1.40) 1.14 (0.89e1.45)
52 5017 36,976 174 1.04 (0.83e1.29) 1.03 (0.80e1.32)
Years of menstruation 14,386 236,732 667 1.01 (0.99e1.03) 1 (0.98e1.03)
OC use
Never 6202 56,109 193 1 Ref 1 Ref
Ever 11,924 96,117 133 1.11 (0.87e1.42) 1.03 (0.79e1.35)
Years of OC use 11,488 90,646 120 0.94 (0.87e1.01) 0.96 (0.89e1.04)
HRT use
Never 22,203 175,094 391 1 Ref 1 Ref
Past 2536 18,035 88 1.12 (0.88e1.41) 1.03 (0.80e1.33)
Current 2003 16,964 95 1.32 (1.05e1.66) 1.19 (0.92e1.53)
HRT use by site
Never 22,203 175,094 391 1 Ref 1 Ref
Local 2197 16,539 100 1.26 (1.01e1.58) 1.16 (0.90e1.48)
Systemic 2342 18,460 83 1.16 (0.91e1.48) 1.05 (0.80e1.36)
Years of HRT use 3370 22,306 116 1.04 (1.01e1.07) 1.04 (1.01e1.07)
* Adjusted for age, BMI and smoking.
y Adjusted for age, BMI, smoking and physical activity in all analyses. Additional adjustment for diabetes, parity, menarche, menopausal status, oral contraceptives and
hormone replacement therapy as appropriate in each DAG analysis.
A.I. Hellevik et al. / Osteoarthritis and Cartilage 25 (2017) 1654e16621658In a sensitivity analysis of 8745 participants from HUNT2 on
parity, oral contraceptive use, and HRT use, adjusted for education
level, we found a reduced risk of TKR in women reporting 1 birth
(HR 0.15, 95% CI 0.09e0.78) or  4 births (HR 0.18, 95% CI
0.22e0.97) compared to nulliparous women, but there was no sig-
nificant trend across the categories (P ¼ 0.37) (Table B, Appendix).
Years of HRT use slightly increased the risk of THR, but past or cur-
rent use of HRT was not associated with THR (Table C, Appendix).
Discussion
This prospective cohort study of over 30,000 women found that
olderageatmenarchewas associatedwithdecreased riskof TKR.We
also found an association between past and systemic HRT use and
increased risk of TKR. Parity did not increase the risk of TKR or THR.
The observation that increasing age at menarche was inversely
related to the risk of TKR has also been reported in a large pro-
spective study of 1.3 million middle-aged women by Liu et al.4. The
mechanisms underlying these associations are unclear, but there
could be several possible explanatory factors. A recent cross-
sectional study found an association between early age at
menarche and chronic widespread musculoskeletal complaints
later in life21. One may therefore speculate that an increased level
of pain from knee osteoarthritis in this group could lead to a
higher incidence of TKR. Early onset of menarche has also been
linked to other conditions of ageing such as elevated bloodpressure and glucose intolerance, independent of body composi-
tion22. A cross-sectional study by Kalichman et al. demonstrated a
negative association between age atmenarche and radiological hand
osteoarthritis. They proposed that one possible explanation could be
that early menarche was associated with an increased rate of the
general ageing process23. Yet another explanation could be that
younger age at menarche may be a marker of other factors such as
higher BMIwhenyoung4;weight gain at a young age has been shown
to be a significant risk factor for TKR and THR due to osteoarthritis
later in life24,25.
Systemic use of HRT increased the risk of TKR, and although we
did not find any association between current use of HRT and joint
replacement, our finding of increased risk of TKR in women with
past use of HRT is in agreement with the results by Liu et al.4. They
reported that past or current use of postmenopausal hormone
therapy was associated with a significant increase in the incidence
of THR and TKR. However, clinical and epidemiological studies have
shown conflicting results, and a systematic review found no clear
association between HRT and osteoarthritis26. Heterogeneity be-
tween the hormones used and outcome measurements also made
statistical data pooling impossible. They concluded that the rela-
tionship was, perhaps, too complex, or that other factors play a role
in the increased incidence of osteoarthritis in women aged >50.
Our study did not observe any association between parity and
joint replacement. Previous studies on the association between
parity and knee osteoarthritis have shown conflicting results3e5.
A.I. Hellevik et al. / Osteoarthritis and Cartilage 25 (2017) 1654e1662 1659However, the absolute numbers of joint replacements in the
nulliparous group in our study were low (n¼ 25 and n¼ 17 for THR
and TKR, respectively), which calls the power of this analysis into
question. We cannot exclude the possibility that this may have
weakened any association. Since both parity and joint replacement
are associated with education level, we did a sub-analysis with
additional adjustment for education in 8745 participants with data
on education level; we revealed a reduced risk of TKR in women
with 1 birth or 4 births, but there was no significant trend across
the categories (P¼ 0.37). This could indicate a complex relationship
between parity and TKR/THR that we were unable to clarify further
in our study.
The healthcare system in Norway is publicly funded and free of
charge for patients. Although socioeconomic status would not
affect access to surgery, it could lead to a difference in those seeking
surgery. In 2009, Statistics Norway reported that amongst women
with musculoskeletal diseases, those with a higher level of edu-
cation (university/college level) were more likely to contact
specialist health services than those with lower levels of education
(high school or lower)27. A negative association between the level of
education and the waiting time for THR in Norway has been re-
ported28, although the income variable was insignificant.
Ever use of OC did not significantly increase the risk of TKR or
THR in the fully adjusted model, although the point estimate of the
P value was borderline significant for TKR, P ¼ 0.053 (HR 1.36, 95%
CI 1.00e1.86). Menopausal status and age at menopause were not
associated with THR or TKR.
Strengths and limitations
Major strengths of this study were the large sample size, pro-
spective population-based design, objective measurements and
nearly complete registration of TKR and THR.
Our study used objectivemeasurements of height andweight by
trained personnel, and thus avoided potential information bias. The
study by Liu et al.4 used self-reported BMI. Self-reported BMI may
be biased, and a recent study showed limited agreement with
actual height and weight in overweight and obese individuals with
clinical osteoarthritis29.
At the time between HUNT2 (1995e1997) and HUNT3
(2006e2008) studies reported an association between HRT and
coronary heart disease30,31, and HRT and breast/gynaecological
cancers32e34. The proportion of women using HRT could therefore
have been lower in the HUNT3 study. In our data-set we found that
19% of participants in HUNT2 were past or current HRT users,
compared to 16.3% in HUNT3. Therefore, HRT prescription did not
differ substantially between the two surveys, and should not have
greatly affected our results.
The design of this study is prospective since the baseline in-
formation was recorded prior to an eventual joint replacement.
However, we cannot exclude the possibility that recall bias might
have influenced some of the covariates, especially age at menarche.
Table I shows a mean age difference of almost 10 years between the
women that reported age at menarche 11 years, and those
reporting age at menarche 15. As well, a Danish study from 2009
showed significantly earlier breast development among girls born
more recently during a 15-year period35. This could indicate that
the age at menarche may have decreased over time in our study
population, thus creating a cohort effect. Adjusting for age may
then be insufficient for correcting an eventual systematic infor-
mation bias and a cohort effect bias.
At baseline, the mean age of our study population was 55.7, and
62.1% of the women in our study were postmenopausal. However,
since our lower cut-off for age at inclusion was 30 years, the in-
formation on reproductive history and use of HRT or OC could havechanged for some participants after baseline. This is especially
relevant when it comes to parity, oral contraceptive use and HRT,
and could have led to non-differential misclassification and thus
weakened any associations. To increase the information on lifetime
reproductive history and eventual use of HRT, we chose to use
baseline measurements from HUNT3 for those that participated in
both HUNT2 and HUNT3, even if this reduced follow-up time after
baseline; the 9468 participants with baseline measurements from
HUNT2 had a mean follow-up time of 13.0 years compared to 6.1
years for the 20,821 participants with baseline measurement from
HUNT3. Lower incidences of TKR (1.2 %) and THR (1.8%) in the
HUNT3 group, compared toTKR (1.8%) and THR (3.2%) in the HUNT2
group, might contribute to lower precision and underestimation of
any associations.
A previous study from the HUNT2 material reported that
women who had undergone unilateral oophorectomy entered
menopause around 1 year earlier than women with two intact
ovaries36 (Separation between uni- vs bilateral oophorectomy was
only available fromHUNT2, as the HUNT3 questionnaire only asked
about bilateral oophorectomy). We chose not to exclude partici-
pants that had had only one ovary surgically removed (n ¼ 776),
and additional adjustment for unilateral oophorectomy when
analysing age at menarche did not change the results (data not
shown).
In HUNT2 we had information on type of HRT medication in
2601 participants. Of these participants, 1456 (56%) used a combi-
nation of oestrogen and progesterone, and 1145 used oestrogen
without progesterone. HUNT3 did not have information about the
precise type of HRT used by each individual. A previous publication
on HRT from HUNT3 reported that data from the Norwegian Pre-
scription Database showed that during the time frame and region
of the HUNT3 study, 83.5% of HRT users were prescribed a combi-
nation of oestradiol and/or oestriol and progesterone, 9.0% either
oestradiol or oestriol without progesterone and 7.5% used the
synthetic oestrogen tibolone37,38.
Although there was a 10-year period between HUNT2 and
HUNT3, they both used the same source population: All inhabitants
20 years of age in the county of Nord-Trøndelag in Norway. But
there could be several reasonswhyHUNT2 andHUNT3 did not have
all the same participants:
- The participation rate in HUNT3 was lower than in HUNT2
(58.7% and 75.5%, respectively). Some of the responders in
HUNT2 could therefore have been non-responders in HUNT3.
- We would expect some of the older participants in HUNT2 to
have died before HUNT3. And people that were too young to
participate in HUNT2 could be part of the study population in
HUNT3.
The population in Nord-Trøndelag is relatively homogeneous,
with less than 3% non-Caucasian, and is relatively stable, with few
people moving in or out of the county39. So despite the limitations
that arise from using the participants from two consecutive waves
of the HUNT health survey, we would argue that the two surveys
represent one source population.
The osteoarthrosis diagnoses from the NAR have not been vali-
dated40. However, the Danish Hip Arthroplasty Registry has re-
ported a positive predictive value of 85% regarding primary hip
osteoarthritis diagnosis41, and it is likely that these results are
comparable to the NAR.
Previous injuries increase the risk of osteoarthritis, especially in
the knee42,43. However, the operating surgeon reports whether
each joint replacement is due to primary/idiopathic osteoarthritis,
or due to other specified causes. We only included joint replace-
ment due to primary/idiopathic osteoarthritis.
A.I. Hellevik et al. / Osteoarthritis and Cartilage 25 (2017) 1654e16621660We used joint replacement as an indicator of severe osteoar-
thritis. Joint replacement is the most definitive treatment for
osteoarthritis in the hip or knee, and has the advantage of being a
strong indicator of severe clinical disease compared to other defi-
nitions of osteoarthritis44. Using total joint replacement as an
endpoint also helps to identify the burden of severe disease, and is
therefore relevant for health economics45. The decision to do a total
arthroplasty does, however, rely on several factors: the severity of
pain, radiographic findings, comorbidities and the patient's moti-
vation for undergoing surgery. Subjects who wish to maintain an
active lifestyle may be more motivated to have surgery than less
active persons46, even if they have less severe osteoarthritis. This
potential healthy patient bias could lead to an underestimation of
the effect of reproductive and hormonal therapies on osteoarthritis.
We found that increasing age at menarche reduced the risk of
TKR. Past users and users of systemic HRTwere at higher risk of TKR
compared to never users. Parity did not increase the risk of TKR or
THR.
Contributors
AIH participated in the study concept and design, obtained
funding, performed the analysis, interpreted the data and drafted
the manuscript. LN, MBJ, AL, GBF, OF, KS and JAZ were involved in
the conception and design of the study. OF was also involved in the
collection of THR and TKR data. AMF contributed with statistical
expertise. All the authors revised the manuscript for important
intellectual content and approved the final version of the
manuscript.Table A
Covariates adjusted for in Model 1 and Model 2 (BMI: Body Mass Index; HRT: Hormone
Exposure variable Covariates adjusted for in Model 1
Parity Age, BMI, smoking
Age at menarche Age, BMI, smoking
Years of menstruation Age, BMI, smoking
Menopausal status Age, BMI, smoking
Age at menopause Age, BMI, smoking
Use of oral contraceptives Age, BMI, smoking
Use of HRT Age, BMI, smoking
Table B
Parity, oral contraceptives (OC), hormone replacement therapy (HRT) and risk of total kn
Population at risk Person years Cas
Parity
Nulliparous 797 9743 14
1 961 13,486 10
2 2602 36,701 40
3 2131 29,165 40
4 1913 22,874 46
P linear trend
OC use
Never 2119 30,002 59
Ever 2176 35,524 21
Years of OC use 1883 30,955 16
HRT use
Never 4897 67,037 81
Past 414 5172 10
Current 704 8760 22
HRT use by site
Never 4897 67,037 81
Local 544 6269 20
Systemic 574 7662 12
Years of HRT use 319 3740 16
* Adjusted for age, BMI, smoking and education level.
y Adjusted for age, BMI, smoking, physical activity and education level in all analys
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Appendixreplacement therapy)
Additional covariates adjusted for in Model 2
Diabetes, physical activity, age at menarche, menopausal status, HRT
Diabetes, physical activity, parity, menopausal status
Diabetes, physical activity, parity
Physical activity, parity, age at menarche, HRT
Physical activity, parity, age at menarche, HRT
Physical activity, parity, age at menarche, menopausal status
Physical activity, parity, menopausal status
ee replacement (TKR); sensitivity analysis with additional adjustment for education
es HR* 95% CI HRy 95% CI
1 Ref 1 Ref
0.52 (0.23e1.18) 0.15 (0.09e0.78)
0.83 (0.45e1.53) 0.20 (0.27e1.12)
0.87 (0.47e1.60) 0.20 (0.26e1.11)
0.77 (0.42e1.41) 0.18 (0.22e0.97)
0.97 0.37
1 Ref 1 Ref
0.92 (0.52e1.62) 0.95 (0.50e1.78)
1.04 (0.95e1.13) 1.05 (0.95e1.16)
1 Ref 1 Ref
1.05 (0.54e2.03) 1.06 (0.50e2.23)
1.38 (0.86e2.24) 1.36 (0.79e2.36)
1 Ref 1 Ref
1.50 (0.91e2.48) 1.56 (0.88e2.76)
0.99 (0.54e1.83) 0.93 (0.46e1.89)
0.96 (0.81e1.14) 0.96 (0.80e1.14)
es. Additional adjustment for diabetes, parity, menarche, menopausal status, oral
Table C
Parity, oral contraceptives (OC), hormone replacement therapy (HRT) and risk of total hip replacement (THR); sensitivity analysis with additional adjustment for education
Population at risk Person years Cases HR* 95% CI HRy 95% CI
Parity
Nulliparous 797 9743 21 1 Ref 1 Ref
1 961 13,486 21 0.83 (0.45e1.53) 1.02 (0.44e2.33)
2 2602 36,701 77 1.16 (0.72e1.89) 1.53 (0.77e3.02)
3 2131 29,165 61 0.97 (0.59e1.59) 1.17 (0.58e2.36)
4 1913 22,874 81 1.03 (0.64e1.67) 1.1 (0.55e2.23)
P linear trend 0.87 0.88
OC use
Never 2119 30,002 91 1 Ref 1 Ref
Ever 2176 35,524 33 0.97 (0.62e1.52) 1.01 (0.63e1.62)
Years of OC use 1883 30,955 25 0.96 (0.87e1.05) 0.95 (0.86e1.04)
HRT use
Never 4897 67,037 144 1 Ref 1 Ref
Past 414 5172 14 0.77 (0.45e1.34) 0.85 (0.47e1.51)
Current 704 8760 35 1.04 (0.72e1.52) 1.03 (0.68e1.57)
HRT use by site
Never 4897 67,037 144 1 Ref 1 Ref
Local 544 6269 26 0.98 (0.64e1.49) 1.07 (0.67e1.71)
Systemic 574 7662 23 0.92 (0.59e1.43) 0.86 (0.53e1.41)
Years of HRT use 319 3740 17 1.13 (1.03e1.25) 1.18 (1.05e1.33)
* Adjusted for age, BMI, smoking and education level.
y Adjusted for age, BMI, smoking, physical activity and education level in all analyses. Additional adjustment for diabetes, parity, menarche, menopausal status, oral
contraceptives and hormone replacement therapy as appropriate in each DAG analysis.
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